Almac has announced expansion of its UK facility and a new non-GMP drug development facility at the Craigavon site, representing an investment of $21.5 million.
Almac has announced further expansion of its UK facility. Together with the new non-GMP drug development facility at the Craigavon site, the two expansions represent a total investment of £13.7million ($21.5 million), which includes some financial support from Invest Northern Ireland. Both projects are expected to create up to 229 jobs over the next three years according to the press release.
Almac stated that it will focus all production in Northern Ireland with additional equipment and resources in Craigavon. The investment will deliver blending equipment, an automated packing and integrated cartoning line which will enable high volume bulk commercial manufacturing, scheduled to begin in November 2013.
The new 13,400 square-feet formulation-development facility and analytical laboratories at Almac’s Craigavon site are also experiencing growth. This non-GMP facility develops tablet and capsule formulations for new drugs in early-stage development, which have not reached the market. The aim is to enable greater speed in formulation and process development, by creating an environment where development work be done quickly and efficiently and free from the constraints associated with drug manufacturing.
According to Graeme McBurney, president and managing director of the business unit, centralizing and expanding the production in Craigavon will be more cost effective for optimal quality control and distribution, given that Almac’s laxative product has been a success in the UK and Europe. “We are also delighted to see the completion of the new non-GMP facility on site which, alongside Almac’s existing GMP capability, will enable us to operate with improved speed and efficiency in the early stages of projects.”
Enterprise Minister Arlene Foster said, “This investment is good news for Craigavon and will reinforce Northern Ireland’s position in the wider life-sciences sector. The 229 new jobs will deliver almost £5.5 million annually in salaries, bringing an important and positive economic boost which will benefit local people.”
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.